Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly is buying Dermira for $1.1 billion in cash to acquire lebrikizumab, a Phase 3 IL-13 antibody for atopic dermatitis. The acquisition extends Lilly's…
Eli Lilly is paying $1.1 billion for Dermira to add lebrikizumab to its immunology pipeline, the company said Friday. The Phase 3 IL-13 antibody is positioned…
Sep 13, 2024: FDA approved Lilly's EBGLYSS (lebrikizumab-lbkz) for adults and children 12 years and older (>=88 lbs) with moderate-to-severe atopic dermatitis…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Eli Lilly agreed to acquire Dermira for $18.75/share in cash, ~$1.1B total. The deal added lebrikizumab, a Phase 3 IL-13 monoclonal antibody for atopic dermatitis, plus marketed product Qbrexza for hyperhidrosis. Bolstered Lilly's immunology/dermatology pipeline alongside Taltz and Olumiant.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Dermira Inc. (this deal) | 2020 | $1.1B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2020 deals · Eli Lilly and Company deals · Dermatology deals